Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IBRX ImmunityBio Inc
- Stocks
- Healthcare
- NASDAQ: IBRX
Price (delayed)
$2.93
Market cap
$2.59B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.54
Enterprise value
$3.35B
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer
Highlights
ImmunityBio's revenue has surged by 112% QoQ
The company's gross profit has surged by 111% QoQ
ImmunityBio's equity has decreased by 21% QoQ but it has increased by 15% YoY
The debt has declined by 8% year-on-year but it rose by 4.3% since the previous quarter
ImmunityBio's quick ratio has decreased by 50% YoY and by 42% from the previous quarter
Key stats
What are the main financial stats of IBRX
Market
Valuations
Earnings
Shares outstanding
882.62M
Market cap
$2.59B
Enterprise value
$3.35B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
80.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
107.23
Revenue
$31.22M
Gross profit
$31.16M
Operating income
-$313.42M
Net income
-$409.1M
EBIT
-$263.63M
EBITDA
-$240.81M
Free cash flow
-$376.91M
Per share
Balance sheet
Liquidity
EPS
-$0.54
EPS diluted
-$0.58
Free cash flow per share
-$0.44
Book value per share
-$0.69
Revenue per share
$0.04
TBVPS
$0.34
Total assets
$303.76M
Total liabilities
$894.24M
Debt
$822.56M
Equity
-$591.43M
Working capital
$59.96M
Debt to equity
-1.39
Current ratio
2.22
Quick ratio
1.61
Net debt/EBITDA
-3.16
Margins
Efficiency
Dividend
EBITDA margin
-771.3%
Gross margin
99.8%
Net margin
-1,310.3%
Operating margin
-1,003.8%
Return on assets
-109.4%
Return on equity
N/A
Return on invested capital
-24%
Return on capital employed
-103.6%
Return on sales
-844.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IBRX stock price
How has the ImmunityBio stock price performed over time
Intraday
8.12%
1 week
19.11%
1 month
15.35%
1 year
-52.36%
YTD
14.45%
QTD
-2.66%
Financial performance
How have ImmunityBio's revenue and profit performed over time
Revenue
$31.22M
Gross profit
$31.16M
Operating income
-$313.42M
Net income
-$409.1M
Gross margin
99.8%
Net margin
-1,310.3%
ImmunityBio's revenue has surged by 112% QoQ
The company's gross profit has surged by 111% QoQ
ImmunityBio's operating margin has soared by 99% YoY and by 57% from the previous quarter
The net margin has surged by 99% year-on-year and by 53% since the previous quarter
Price vs fundamentals
How does IBRX's price correlate with its fundamentals
Growth
What is ImmunityBio's growth rate over time
Valuation
What is ImmunityBio stock price valuation
P/E
N/A
P/B
N/A
P/S
80.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
107.23
ImmunityBio's EPS has surged by 50% YoY and by 8% QoQ
ImmunityBio's equity has decreased by 21% QoQ but it has increased by 15% YoY
ImmunityBio's revenue has surged by 112% QoQ
The P/S is 98% less than the 5-year quarterly average of 4632.6 and 92% less than the last 4 quarters average of 968.9
Efficiency
How efficient is ImmunityBio business performance
ImmunityBio's return on sales has surged by 99% YoY and by 52% QoQ
The company's return on invested capital has surged by 56% YoY but it fell by 3.4% QoQ
IBRX's return on assets is up by 26% year-on-year but it is down by 5% since the previous quarter
Dividends
What is IBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IBRX.
Financial health
How did ImmunityBio financials performed over time
The total assets is 66% less than the total liabilities
ImmunityBio's quick ratio has decreased by 50% YoY and by 42% from the previous quarter
The current ratio has decreased by 39% YoY and by 34% from the previous quarter
ImmunityBio's equity has decreased by 21% QoQ but it has increased by 15% YoY
The company's debt to equity rose by 14% QoQ but it fell by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.